title: Impact of adenosine receptors on immunoglobulin production by human peripheral blood B lymphocytes.
abstract: Adenosine is an endogenous compound that regulates function of several immune cells including lymphocytes by activating adenosine receptors (ARs). Several reports indicate that stimulation of ARs on lymphocytes affects lymphocyte activation, proliferation and lymphocyte-mediated cytolysis. Unfortunately, most studies focused on T lymphocytes and little information exists on involvement of ARs in B cells regulation. In this study we elucidated the impact of ARs activation on immunoglobulin M (IgM) production by purified human peripheral blood B lymphocytes stimulated in vitro with Staphyloccocus aureus Covan I (SAC) plus IL-2. Performed experiments showed that endogenous adenosine that is released/produced by human B lymphocytes is able to induce cAMP accumulation in the cell through activation of A2A-AR however, this takes place only when other ARs are inhibited by selective antagonists. We observed that accumulated intracellular cAMP suppressed IgM production by B cells stimulated with SAC plus IL-2. Our experiments showed that human B cells cultured at 25 mM glucose produced significantly less IgM in response to stimulation with SAC comparing to cells maintained in media containing 5 mM glucose. However, the high glucose effect on IgM production by B cells stimulated with SAC depended on other factor/s than ARs.
authors: Department of Molecular Medicine, Medical University of Gdansk, Gdansk, Poland.
authors: M
authors: M
authors: Sakowicz-Burkiewicz
authors: K
authors: K
authors: Kocbuch
authors: M
authors: M
authors: Grden
authors: I
authors: I
authors: Maciejewska
authors: A
authors: A
authors: Szutowicz
authors: T
authors: T
authors: Pawelczyk
mesh_terms: D000241:Adenosine / Q000378:metabolism; D000942:Antigens, Bacterial / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007075:Immunoglobulin M / Q000096:biosynthesis*; D007376:Interleukin-2 / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D058906:Purinergic P1 Receptor Agonists / Q000494:pharmacology; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000378:metabolism*; D013211:Staphylococcus aureus / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; D007075:Immunoglobulin M; D007376:Interleukin-2; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D000242:Cyclic AMP; D005947:Glucose; D000241:Adenosine